Results 11 to 20 of about 923 (130)

Azvudine for the Treatment of COVID‐19 in Pre‐Existing Cardiovascular Diseases: A Single‐Center, Real‐World Experience [PDF]

Advanced Science
COVID‐19 can lead to adverse outcomes in patients with pre‐existing diseases. Azvudine has been approved for treating COVID‐19 in China, but the real‐world data is limited. It is aimed to investigate the efficacy of Azvudine in patients with COVID‐19 and
Liu Wu, Zhong‐Han He, Ling Huang, Xin Guo, Xu‐Yong Li, Hong‐Da Zhang, Man‐Hua Chen   +6 more
doaj   +6 more sources

The Antiviral Efficacy and Safety of Azvudine in Hospitalized SARS‐CoV‐2 Infected Patients with Liver Diseases Based on a Multicenter, Retrospective Cohort Study [PDF]

Advanced Science
Despite azvudine being prioritized for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, its effectiveness and safety remain inadequately substantiated in hospitalized SARS‐CoV‐2 infected patients with liver ...
Junyi Sun, Mengzhao Yang, Guanyue Su, Ling Wang, Xiaobo Hu, Yongjian Zhou, Guangying Cui, Guowu Qian, Yiqiang Yuan, Xinjun Hu, Silin Li, Hong Luo, Shixi Zhang, Guangming Li, Donghua Zhang, Guotao Li, Ming Cheng, Zujiang Yu, Zhigang Ren   +18 more
doaj   +4 more sources

Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19 [PDF]

Scientific Reports
Cancer significantly contributes to the unfavorable prognosis of coronavirus disease 2019 (COVID-19) patients. The efficacy and safety of azvudine and nirmatrelvir/ritonavir (Paxlovid) in cancer patients with COVID-19 remain uncertain.
Bohan Jia, Junyi Sun, Di Zhu, Ling Wang, Xiaobo Hu, Haiyu Wang, Guowu Qian, Donghua Zhang, Silin Li, Hong Luo, Shixi Zhang, Guotao Li, Guangming Li, Hongxia Liang, Zujiang Yu, Zhigang Ren   +15 more
doaj   +5 more sources

Antiviral effectiveness and safety of azvudine in hospitalized SARS‐CoV‐2 patients with pre‐existing chronic respiratory diseases: A multicenter, retrospective cohort study [PDF]

View
Although azvudine has become a priority in the treatment of SARS‐CoV‐2, its effectiveness and safety among COVID‐19 patients who already have chronic respiratory diseases (CRDs) have not been sufficiently validated.
Junyi Sun, Mengzhao Yang, Daoke Yao, Yongjian Zhou, Xiaobo Hu, Guowu Qian, Yiqiang Yuan, Silin Li, Hong Luo, Shixi Zhang, Guangming Li, Donghua Zhang, Guotao Li, Yanyang Zhang, Xinjun Hu, Zujiang Yu, Guangying Cui, Zhigang Ren   +17 more
doaj   +4 more sources

Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients [PDF]

BMC Infectious Diseases
Purpose To explore the effect of azvudine as compared to paxlovid for oral treatment of hospitalized patients with SARS-CoV-2 infection. Methods We analyzed data from a cohort of patients with SARS-CoV-2 infection in Shandong provincial hospital between ...
Peng Su, Cong-xian Yang, Xing-guang Wang
doaj   +5 more sources

Azvudine efficacy in reducing mortality in COVID-19 patients [PDF]

European Journal of Medical Research
Background Several therapeutic drugs have been authorized for the treatment of patients with Coronavirus disease 2019 (COVID-19). However, further research on the mechanisms of action, efficacy, and target populations of these novel therapeutic drugs are
Zhen Zhong, Xiao-feng Liu, Xiao-zhong Zhou, Jia-ning Zhong, Li-cheng Zhou, Rong Li, Xian-fa Liu   +6 more
doaj   +6 more sources

Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine [PDF]

Frontiers in Cellular and Infection Microbiology, 2023
BackgroundAzvudine has been approved in China for the treatment of COVID-19 patients. Previous studies have suggested a correlation between high levels of lactate dehydrogenase (LDH) and the severity of COVID-19.
Manyun Mao, Manyun Mao, Manyun Mao, Manyun Mao, Manyun Mao, Yating Dian, Yating Dian, Yating Dian, Yating Dian, Yating Dian, Yuming Sun, Yuming Sun, Yuming Sun, Yuming Sun, Yuming Sun, Wangqing Chen, Wangqing Chen, Wangqing Chen, Wangqing Chen, Wangqing Chen, Wu Zhu, Wu Zhu, Wu Zhu, Wu Zhu, Wu Zhu, Guangtong Deng, Guangtong Deng, Guangtong Deng, Guangtong Deng, Guangtong Deng   +29 more
doaj   +4 more sources

Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study [PDF]

Scientific Reports
This study aimed to explore the effectiveness and safety of azvudine, nirmatrelvir/ritonavir, and molnupiravir in adult patients with mild-to-moderate COVID-19.
Mei-Ping Chen, Di-Xuan Jiang, Jia-Xi Rang, Hai-Bo Zhuo, Zhi-Guo Zhou   +4 more
doaj   +5 more sources

Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19 [PDF]

BMJ Open Respiratory Research
Background In China, both nirmatrelvir-ritonavir (Paxlovid) and azvudine have been granted approval to treat adult SARS-CoV-2-infected patients with moderate symptoms.
Junjun Chen, Zheng Zhang, Huan Zhang, Yao Li, Yan Kang, Jianbo Li, Tan Xiaojiao, Chenxi Wang, Haiqing Shi, Xiaodong Jin, Xuelian Liao   +10 more
doaj   +5 more sources

Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world studyResearch in context [PDF]

EClinicalMedicine
Summary: Background: Azvudine and nirmatrelvir/ritonavir are approved to treat mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with a high risk for progression to severe infection.
Shuxia Wang, Jin Sun, Xin Zhang, Man Li, Bangguo Qin, Miao Liu, Nan Zhang, Shengshu Wang, Tingyu Zhou, Wei Zhang, Cong Ma, Xinli Deng, Yongyi Bai, Geping Qu, Lin Liu, Hui Shi, Bo Zhou, Ke Li, Bo Yang, Suxia Li, Fan Wang, Jinling Ma, Lu Zhang, Yajuan Wang, Li An, Wenhui Liu, Qing Chang, Ru Zhang, Xi Yin, Yang Yang, Qiangguo Ao, Qiang Ma, Shuangtong Yan, Haili Huang, Peng Song, Linggen Gao, Wenning Lu, Lining Xu, Li Lei, Keyu Wang, Qi Zhang, Qing Song, Zhijian Zhang, Xiangqun Fang, Yao He, Tianzhi Li, Ping Zhu   +46 more
doaj   +5 more sources